The retailer delivered its first annual sales rise since 2020, but slipping active customers signal growth isn’t yet secure.

The secondhand marketplace is being snapped up by eBay to bolster its standing among Gen Z shoppers.

Revenue hit $1.08B, but losses and soft guidance sank shares as credit stress ticked up.

Instagram cools, Facebook steadies, X stalls—making channel focus a strategic call, not a cosmetic one.

Omnicom's scale expanded faster than organic growth; its IPG deal-driven revenue surge contrasts with modest underlying performance in its core business.

Its no-code tool brings scenario planning to marketers, aiming to turn episodic modeling into daily decisions.

After an unusual review rejection, the FDA reverses course—a regulatory whiplash that could raise concerns about regulatory consistency.

The Eucalyptus deal deepens global reach as diversification beyond compounded GLP-1s in the US becomes urgent.

As AI tools steer more healthcare decisions, providers and insurers must target high-value use cases, carefully vet vendors, and lock in governance early.

Healthcare and pharma marketers should ramp up social listening and host expert Ask Me Anything sessions to drive engagement without feeling intrusive.

The FDA’s plans for broader access of medications could boost convenience, but also raise safety risks and drug costs.

67% of top sports podcast shows are for niche sports, where high engagement, loyal fans, and off-season spikes lift ROI.

Walmart’s ad business is entering its scale phase: Growth is moderating, but monetization is broadening across search, display, offsite, and CTV.